{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:39:00Z","timestamp":1786995540540,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.pharma.2023.10.006","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:15:08Z","timestamp":1697800508000},"page":"464-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Stability Indicating RP-HPLC-DAD method for simultaneous estimation of tadalafil and macitentan in synthetic mixture for treatment of pulmonary arterial hypertension"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-7313","authenticated-orcid":false,"given":"Dhruvanshi","family":"Gol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilam","family":"Visana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devang","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Dholakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2023.10.006_bib0120","series-title":"Pulmonary Pharmacology","first-page":"1059","article-title":"Good man and Gilman's the pharmacological basis of therapeutics","author":"Brunton","year":"2011"},{"key":"10.1016\/j.pharma.2023.10.006_bib0125","unstructured":"United States Food and Drug Administration (2022) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03904693?term=tadalafil+and+macitentan&cond=Pulmonary+Arterial+Hypertension&draw=2&rank=1 (accessed December 22, 2022)."},{"key":"10.1016\/j.pharma.2023.10.006_bib0130","series-title":"Martindale the complete drug references","author":"Kathleen","year":"2009"},{"issue":"2","key":"10.1016\/j.pharma.2023.10.006_bib0135","first-page":"1223","article-title":"RP-HPLC Estimation of tadalafil in tablet dosage form","volume":"6","author":"Sutar","year":"2008","journal-title":"Int J Chem Sci"},{"issue":"2","key":"10.1016\/j.pharma.2023.10.006_bib0140","first-page":"230","article-title":"Rapid estimation of tadalafil by RP-HPLC method in bulk and tablet formulation","volume":"75","author":"Sonawane","year":"2013","journal-title":"Indian J Pharm Sci"},{"issue":"12","key":"10.1016\/j.pharma.2023.10.006_bib0145","first-page":"072","article-title":"RP-HPLC-PDA method development and validation for the analysis of tadalafil in bulk, pharmaceutical dosage forms and in vitro dissolution sample","volume":"4","author":"Unnisa","year":"2014","journal-title":"J Appli Pharm Sci"},{"issue":"3","key":"10.1016\/j.pharma.2023.10.006_bib0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/00032710903402283","article-title":"Rapid resolution RP-HPLC-DAD method for simultaneous determination of sildenafil, vardenafil, and tadalafil in pharmaceutical preparations and counterfeit drugs","volume":"43","author":"Yang","year":"2010","journal-title":"Anal Lett"},{"issue":"7","key":"10.1016\/j.pharma.2023.10.006_bib0155","first-page":"443","article-title":"Spectrophotometric methods for the determination of Tadalafil in pharmaceutical forms","volume":"6","author":"Fraihat","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"issue":"4","key":"10.1016\/j.pharma.2023.10.006_bib0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5958\/2231-5675.2020.00032.0","article-title":"A stress degradation kinetic study of Tadalafil bulk and tablet dosage form by UV spectrophotometry","volume":"10","author":"Vyas","year":"2020","journal-title":"Asian J Pharm Anal"},{"key":"10.1016\/j.pharma.2023.10.006_bib0165","first-page":"749","article-title":"Stability indicating RP-HPLC method for the determination of ambrisentan and tadalafil in pharmaceutical dosage form","volume":"82","author":"Patel","year":"2014","journal-title":"Sei Pharm"},{"issue":"2","key":"10.1016\/j.pharma.2023.10.006_bib0170","first-page":"149","article-title":"Development and validation of a stability indicating RP-HPLC method for analysis of Tadalafil in bulk and tablet dosage form","volume":"4","author":"Kharat","year":"2017","journal-title":"Eur J Biomed Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharma.2023.10.006_bib0175","first-page":"001","article-title":"Validation and stability indicating RP-HPLC method for the determination of tadalafil API in pharmaceutical formulation","volume":"2","author":"Reddy","year":"2010","journal-title":"Res Pharm Biotechnol"},{"issue":"5","key":"10.1016\/j.pharma.2023.10.006_bib0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jpba.2017.05.052","article-title":"Simultaneous quantification of endothelin receptor antagonist and phosphodiesterase 5 inhibitor currently used in pulmonary hypertension","volume":"143","author":"Enderle","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2023.10.006_bib0185","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchromb.2015.07.053","article-title":"Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatographytandem mass spectrometry","volume":"1002","author":"Lixiu","year":"2015","journal-title":"J Chromatogr B"},{"issue":"4","key":"10.1016\/j.pharma.2023.10.006_bib0190","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/10826070500479393","article-title":"Determination of Sildenafil, Tadalafil and Vardenafil in Tablets and Adulterated Herbal Products by ESI-MS-MS","volume":"29","author":"Abdel Hamid","year":"2016","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"10.1016\/j.pharma.2023.10.006_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bmc.4502","article-title":"A novel, rapid and sensitive UPLC-MS\/MS method for the determination of macitentan in patients with pulmonary arterial hypertension","volume":"33","author":"Albayrak","year":"2019","journal-title":"Biomed Chromatogr"},{"issue":"10","key":"10.1016\/j.pharma.2023.10.006_bib0200","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/10826076.2012.692143","article-title":"Simultaneous determination of tadalafil and its related compounds in pharmaceutical dosage forms by UPLC","volume":"36","author":"Satheesh","year":"2013","journal-title":"J Liq Chromatogr Relat Technol"},{"issue":"1","key":"10.1016\/j.pharma.2023.10.006_bib0205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.12793\/tcp.2017.25.1.21","article-title":"Validated UPLC-MS\/MS method for the determination of tadalafil in human plasma and its application to a pharmacokinetic study","volume":"25","author":"Kim","year":"2017","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.pharma.2023.10.006_bib0210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jpba.2011.05.036","article-title":"Development and validation of a GC\/MS method for the determination of tadalafil in whole blood","volume":"56","author":"Nikolaou","year":"2011","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"10.1016\/j.pharma.2023.10.006_bib0215","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/22297928.2019.1652683","article-title":"Quantification of genotoxic Impurities in tadalafil by simple and sensitive gas chromatography technique","volume":"9","author":"Anerao","year":"2019","journal-title":"Anal Chem Lett"},{"issue":"1","key":"10.1016\/j.pharma.2023.10.006_bib0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.25004\/IJPSDR.2018.100103","article-title":"Quality by design approach for an orally disintegrating tablet analytical method validation","volume":"10","author":"Demirel","year":"2018","journal-title":"Int J Pharm Sci Drug Res"},{"issue":"4","key":"10.1016\/j.pharma.2023.10.006_bib0225","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/22297928.2021.1938215","article-title":"Implementing analytical quality by design (AQbD) approach for simultaneous estimation of tadalafil and macitentan by RP-HPLC method","volume":"11","author":"Vyas","year":"2021","journal-title":"Anal Chem Lett"},{"key":"10.1016\/j.pharma.2023.10.006_bib0230","unstructured":"ICH harmonized tripartite guidelines (2005). Q2 (R1) validation of analytical procedures: text and methodology."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450923001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450923001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:31:46Z","timestamp":1730370706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450923001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0003450923001141"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2023.10.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stability Indicating RP-HPLC-DAD method for simultaneous estimation of tadalafil and macitentan in synthetic mixture for treatment of pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2023.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}